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Post-ischemic inﬂammation is important in ischemic stroke pathology. However, details
of the inﬂammation process, its resolution after stroke and its effect on pathology and
neural damage have not been clariﬁed. Brain swelling, which is often fatal in ischemic
stroke patients, occurs at an early stage of stroke due to endothelial cell injury and severe
inﬂammation by inﬁltrated mononuclear cells including macrophages, neutrophils, and
lymphocytes. At early stage of inﬂammation, macrophages are activated by molecules
released from necrotic cells [danger-associated molecular patterns (DAMPs)], and inﬂam-
matory cytokines and mediators that increase ischemic brain damage by disruption of the
blood–brain barrier are released. After post-ischemic inﬂammation, macrophages function
as scavengers of necrotic cell and brain tissue debris. Such macrophages are also involved
in tissue repair and neural cell regeneration by producing tropic factors. The mechanisms
of inﬂammation resolution and conversion of inﬂammation to neuroprotection are largely
unknown. In this review, we summarize information accumulated recently about DAMP-
induced inﬂammation and the neuroprotective effects of inﬂammatory cells, and discuss
next generation strategies to treat ischemic stroke.
Keywords: damage-associated molecular patterns (DAMPs), inflammation, cytokines, inflammasome, resolution
of inflammation
INTRODUCTION
Inﬂammation is implicated in almost all of central nervous sys-
tem (CNS) diseases (Lo, 2010; Moskowitz et al., 2010; Iadecola
and Anrather, 2011). Neurodegeneration, infection, trauma, and
ischemia stimulate immune responses in the brain, although to
varying degrees. The process in neuronal injury involves various
intracellular mechanisms (abnormal metabolism and degenera-
tion of protein, dysfunction of organelles, etc.), which cause the
activation of microglia and the inﬁltration of circulating immune
cells (Lo, 2010). Inﬂammation may not be always main process in
the pathology of CNS diseases; nonetheless, the distinct charac-
teristics of ischemic stroke are large amount of necrotic neuronal
death and extreme inﬁltration of immune cells (Moskowitz et al.,
2010; Iadecola and Anrather, 2011).
Severe inﬂammation causes cerebral swelling, which is often
fatal in ischemic stroke patients. Broad necrotic lesion gener-
ates abundant inﬂammatory mediators and damage-associated
molecular patterns (DAMPs), which enhance the chemotaxis of
circulating immune cells and make them more efﬁcient partici-
pants to promote inﬂammation (Moskowitz et al., 2010; Iadecola
and Anrather, 2011). Cerebral inﬂammation exaggerates vascular
dysfunction and induces further neuronal cell death (Dirnagl et al.,
1999). Thus, post-ischemic inﬂammation is an essential process in
the pathophysiology of ischemic stroke and is closely related to the
prognosis after stroke (Dirnagl et al., 1999; Lo, 2010; Moskowitz
et al., 2010; Iadecola and Anrather, 2011). In addition, inﬂamma-
tion is generally considered useful for the clearance of the large
amount of debris caused by brain cell necrotic death (Moskowitz
et al., 2010; Iadecola and Anrather, 2011). Inﬂammation, resolu-
tion of inﬂammation, and repair of neural damage are sequential
pivotal events after stroke. To clarify the detailed mechanisms of
each step of cerebral inﬂammation is indispensable to develop next
generation therapies for ischemic stroke. The molecular basis of
these steps is now being clariﬁed by the recent accumulating evi-
dences. We summarize these ﬁndings and discuss the principles of
post-ischemic inﬂammation from beginning to end.
INFLAMMATORY DAMPs
Brain ischemia induces various large metabolic changes in brain
cells. Hypoxic stress, nutrients stress, and ER stress will cause cell
death and trigger post-ischemic inﬂammation. Although receptors
for pathogens such as Toll-like receptors (TLRs) are thought to be
involved in early step of inﬂammation, brain is a sterile organ.
Thus, endogenous molecules, i.e., DAMPs derived from injured
brain cells, must trigger the inﬂammatory response in immune
cells (Table 1). These DAMPs induce the activation of TLRs and
other pattern recognition receptors [receptor for advanced glyca-
tion end products (RAGE) and c-type lectin receptors], which
promote inﬂammatory mediator expression and tissue injury
(Figure 1; Tang et al., 2007; Yanai et al., 2009; Suzuki et al., 2013).
Recent scientiﬁc advances have suggested the existence of various
types of DAMPs in ischemic brain.
NUCLEIC ACIDS AND NUCLEOTIDES
Various intracellular components are released into the
extracellular space by necrotic brain cell death. Among these,
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Table 1 | List of inflammatory DAMPs.
DAMPs Receptor Reference
Signal 1 Nucleic acid Mitochondrial DNA TLR9 Zhang et al. (2010), Sun et al. (2013), Maeda and Fadeel (2014), Walko et al.
(2014), Wenceslau et al. (2014)
Self RNA, DNA TLR7,9 Hyakkoku et al. (2010), Kawai and Akira (2010), Brea et al. (2011), Stevens et al.
(2011), Leung et al. (2012)
Lipid Carboxyalkylpyrroles TLR2 West et al. (2010)
Oxidized phospholipids CD36 Cho et al. (2005), Gao et al. (2006), Abe et al. (2010), Haider et al. (2011), Miller
et al. (2011), Ho et al. (2012), Matt et al. (2013)
Protein HMGB1 TLR2,4, RAGE Qiu et al. (2008), Zhang et al. (2011)
Peroxiredoxin TLR2,4 Shichita et al. (2012), Kuang et al. (2014)
S100A8, A9 TLR4 Tsai et al. (2014)
Mrp8, 14 TLR4 Loser et al. (2010)
CIRP TLR2,4 Qiang et al. (2013)
Signal 2 Nucleotide ATP P2X, P2Y Martinon et al. (2002), Abulaﬁa et al. (2009), Ceruti et al. (2009), Denes et al.
(2013), Fann et al. (2013), Yang et al. (2014),
Lipid Phospholipids ? Clemens et al. (1996), Bonventre et al. (1997), Muralikrishna Adibhatla and
Hatcher (2006), Shanta et al. (2012), Iyer et al. (2013), Zhong et al. (2013)
Protein ASC specks ? Baroja-Mazo et al. (2014), Franklin et al. (2014)
FIGURE 1 | Mechanisms of post-ischemic inflammation. DAMPs are
released into extracellular compartment and activate inﬁltrating immune
cells by two ways: Signal 1 (via the activation of pattern recognition
receptor) and Signal 2 (via the activation of inﬂammasome). Various
inﬂammatory cytokines promote neuronal injury, and induce further
inﬂammation mediated byT cells in subacute phase. After days and week
after stroke onset, the resolution of post-ischemic inﬂammation is brought
by the clearance of debris including DAMPs or inﬂammatory mediators,
and the production of anti-inﬂammatory molecules or neurotrophic factors.
In this recover phase, inﬂammatory immune cells turn into neuroprotective
cells.
nucleic acids and nucleotides are major DAMPs that have recently
received much attention. Mitochondrial DNA released by cellu-
lar injury can be detected as DAMPs by immune cells, because
mitochondria are considered to have a symbiotic origin that
carries numerous characteristics resembling bacteria. Mitochon-
drial DNA is a sensor molecule of innate immunity by activating
TLR9 and can be detected in cerebrospinal ﬂuid after traumatic
brain injury (Zhang et al., 2010; Walko et al., 2014). Vascular per-
meability is also increased by circulating mitochondrial DNA
after injury (Sun et al., 2013; Wenceslau et al., 2014). Recently
accumulated data indicates that mitochondrial DAMPs could
be an important candidate for the trigger of post-ischemic
inﬂammation, even if there is not yet any direct evidence
(Maeda and Fadeel, 2014).
Self RNA and DNA (in complex with LL37 peptide) acti-
vate immune cells via TLR7 or TLR9 (Kawai and Akira, 2010).
TLR7 is associated with the deterioration in ischemic stroke
patients; in contrast, ischemic brain damage was not reduced
in TLR9-deﬁcient mice (Hyakkoku et al., 2010; Brea et al., 2011).
Several reports demonstrate the implications of TLR7 and TLR9
in ischemic preconditioning. In these articles, the pretreatment
using a TLR7 or TLR9 agonist reveals signiﬁcant neuroprotection
after cerebral ischemia by activating interferon regulatory factor
3/7- (IRF3/7)-induced type I interferon (IFN) signaling pathway
(Stevens et al., 2011; Leung et al., 2012). Although the interaction
between self nucleic acids and TLRs in the ischemic brain remains
controversial, ischemic preconditioning via the TLR7 or TLR9
signaling pathway may represent a therapeutic strategy.
Purines (ATP and UTP) released from injured brain cells and
their receptors, P2X and P2Y, function as alerting signals in CNS
(Ceruti et al., 2009). Importantly, ATP also activates inﬂamma-
somes, which are large multimolecular complexes that control the
activity of the proteolytic enzyme caspase-1 that cleaves pro-IL-1β
to an active 17 kDa form (Martinon et al., 2002). The activation of
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 319 | 2
Shichita et al. Inﬂammatory mechanisms after ischemic stroke
theNLRP1 orNALP3 inﬂammasomehas been recently reported to
promote post-ischemic inﬂammation and neuronal death (Abu-
laﬁa et al., 2009; Fann et al., 2013; Yang et al., 2014). Because IL-1β
produced from both inﬁltrating immune cells and brain cells is
important (Denes et al., 2013), it should be clariﬁed how the
inﬂammasome is activated in ischemic brain or hematopoietic
cells. Inhibition of the inﬂammasome activation pathway may be
a possible therapeutic strategy for ischemic stroke.
LIPIDS
Various types of lipids are also important regulators of innate
immunity. For example, oxidized low density lipoprotein (oxLDL)
is a popular inﬂammatory mediator, which activates TLRs
through binding with its receptor, CD36 (Stewart et al., 2010).
Although the function of oxLDL in ischemic brain remains
unclear, recent research has indicated that end products of
lipid oxidation may be implicated in cerebral post-ischemic
inﬂammation (Uchida, 2013). Carboxyalkylpyrroles, which are
generated in inﬂammatory tissue, activate TLR2 and promote
angiogenesis in ischemic organs (West et al., 2010). Oxidized
phospholipids are also generated during cerebral inﬂammation
and are considered to be DAMPs (Gao et al., 2006; Haider et al.,
2011; Ho et al., 2012). Oxidized phospholipids are CD36 lig-
ands that promote inﬂammation via TLR2 activation in ischemic
brain (Cho et al., 2005; Abe et al., 2010). The recognition and
endocytosis of oxidized lipids by pattern recognition receptors
could regulate post-ischemic inﬂammation (Miller et al., 2011;
Matt et al., 2013).
Phospholipids could also be inﬂammasome activators. Phos-
pholipid metabolism is drastically altered by cerebral ischemia
(Shanta et al., 2012). There are several reports showing the acti-
vation of phospholipase A2 (PLA2) in ischemic brain, which
results in hydrolysis of membrane phospholipids (Clemens
et al., 1996; Bonventre et al., 1997; Muralikrishna Adibhatla
and Hatcher, 2006). Phospholipid hydrolysis and mitochon-
drial dysfunction induced by cerebral ischemia generate reac-
tive oxygen species (ROS). Two recent studies have identi-
ﬁed both ROS-dependent and ROS-independent pathways for
inﬂammasome activation. The former is demonstrated by a
charged phospholipid liposome that consecutively induces ROS-
dependent calcium inﬂux and NLRP3 inﬂammasome activation
(Zhong et al., 2013). In the latter case, mitochondrial cardi-
olipin has been reported to directly bind to and activate the
NLRP3 inﬂammasome (Iyer et al., 2013). Thus, the metabolism
and modiﬁcation of lipids during cerebral ischemia may be
closely associated with the post-ischemic inﬂammation start
signal.
PROTEINS
High mobility group box 1 (HMGB1) and peroxiredoxin (Prx)
family proteins are two major DAMPs in ischemic brain. There is
a difference in the functional phase of these two proteins (Shi-
chita et al., 2012). HMGB1, which is included in the nucleus
of brain cells, is released extracellularly at the hyperacute phase
(several hours after the stroke onset; Qiu et al., 2008). On the
other hand, Prx family proteins function at the acute and suba-
cute phases (12–72 h after the onset), especially in the penumbral
area (Shichita et al., 2012). This is because Prx family pro-
tein expression is induced by an intracellular increase in ROS,
which results from ischemic change. HMGB1 directly breaks
down the blood–brain barrier and increases vascular permeability
(Zhang et al., 2011). However, Prx directly induces the activa-
tion of inﬁltrating immune cells via TLR signaling. Ligustilide has
been reported as a therapeutic candidate that suppresses cerebral
post-ischemic inﬂammation by inhibiting the Prx/TLR4 signaling
pathway (Kuang et al., 2014).
S100A8, S100A9, Mrp8, Mrp14, and cold-inducible RNA bind-
ing protein (CIRP) have also been reported to be protein DAMPs,
although their relevance in post-ischemic inﬂammation has not
yet been clariﬁed (Loser et al., 2010; Qiang et al., 2013; Tsai et al.,
2014). Inﬂammatory responses by these protein DAMPs occur
through the activation of TLR2, TLR4, andRAGE. TLR2 andTLR4
signaling pathways are essential for sterile inﬂammation, includ-
ing ischemic stroke (Chen et al., 2007). TLR2-blocking antibody
is neuroprotective against ischemic brain injury (Ziegler et al.,
2011). Similarly, resatorvid, which inhibits the TLR4 signaling
pathway, attenuates ischemic brain injury and also suppresses
Nox4-induced oxidative stress and neuronal apoptosis (Suzuki
et al., 2012). It is also possible thatDAMP-mediatedTLRactivation
requires other adaptor molecules (Chun and Seong, 2010). CD14,
a TLR4 co-receptor, may be implicated in post-ischemic inﬂam-
mation (Reed-Geaghan et al., 2009). Heat shock protein gp96 is
another candidate molecule that functions as an adaptor for both
TLR2 and TLR4 (Yang et al., 2007).
It is not knownwhether proteinDAMPs can activate inﬂamma-
somes. Recently, aggregated ASC (apoptosis-associated speck-like
protein containing a caspase recruitment domain) has been
reported to be released into the extracellular space after cell death
and it activates inﬂammasomes in the surrounding immune cells
(Baroja-Mazo et al., 2014; Franklin et al., 2014). Inﬂammasome
activation, which occurs through ASC polymerization, results
in caspase-1 activation and pyroptotic cell death. Extracellularly
released ASC is internalized by surrounding macrophages and
induces lysosomal damage and inﬂammasome activation. These
mechanisms of inﬂammasome activation remain to be elucidated
in ischemic brain injury.
OTHER INFLAMMATORY DAMPs
Basic research may neglect the inﬂuence of aging and life habits by
using healthy young rodents. These are important factors for the
generation of DAMPs. Aging and continuous high serum glucose
levels increase lipid peroxidation andAGEs in body systems (Basta
et al., 2004; Cai et al., 2014). AGEs are proteins that are modiﬁed
by sugar, through the Amadori and Maillard reaction. AGEs are
found in chronic lesions; for example, the amyloid deposits that
are surrounded by macrophages in patients with dialysis-related
amyloidosis (Miyata et al., 1993). Thus, AGEs usually take a long
time (more than a month) to generate; however, AGEs can be gen-
erated in a short period of time during inﬂammation (Weil, 2012).
Glyoxal and glyceraldehyde induce AGE formation within 1 week
(Takeuchi et al., 2001). In addition, the pivotal role of the RAGE
in post-ischemic inﬂammation has been demonstrated (Muham-
mad et al., 2008). AGEs can be a potential DAMP, especially in aged
human ischemic stroke patients.
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INFLAMMATION SUPPRESSION AND RESOLUTION
Activated immune cells and brain cells are the major play-
ers after various DAMPs trigger post-ischemic inﬂammation.
These cells produce inﬂammatory cytokines, chemokines, and
other cytotoxic mediators, and this leads to prolonged inﬂam-
mation and progressive brain edema during several days after
the stroke onset (Figure 1). However, post-ischemic inﬂam-
mation rarely lasts for a long period of time, and the most
intense inﬂammatory phase takes place within 7 days after stroke
onset (Dirnagl et al., 1999; Iadecola and Anrather, 2011). In
this phase, the number of inﬁltrating immune cells decreases
remarkably, and remaining immune cells in ischemic brain
produce anti-inﬂammatory or neurotrophic factors (Shichita
et al., 2009; Smirkin et al., 2010). For example, the detailed
mechanisms about the inﬁltration and the change to anti-
inﬂammatory phenotype of neutrophils have been recently clar-
iﬁed (Cuartero et al., 2013; Gorina et al., 2014). The period
of cerebral post-ischemic inﬂammation always ends, and thus,
the mechanisms of its resolution must exist in ischemic
brain.
Three major points on the resolution of inﬂammation have
been discussed in a recent publication (Buckley et al., 2012).
These points are the production of anti-inﬂammatory media-
tors, the depletion of inﬂammatory mediators, and the induction
of anti-inﬂammatory immune cells. After post-ischemic inﬂam-
mation, inﬁltrating macrophages turn into anti-inﬂammatory
macrophages, which produce neurotropic factors and clear
necrotic debris. Inﬂammatory DAMPs will also be implicated
in the induction of anti-inﬂammatory macrophages, although
its mechanism still remains to be clariﬁed. We introduce recent
advantages of the relationship between post-ischemic inﬂamma-
tion and its resolution.
ANTI-INFLAMMATORY MEDIATOR PRODUCTION
Many molecules have been reported to be neuroprotective factors.
However, most of these molecules failed to improve neurological
deﬁcits in ischemic stroke patients, even if they are effective in
animal stroke models. It has been suggested that neuroprotection
alone is not sufﬁcient to improve the prognosis of human ischemic
stroke. Anti-inﬂammatory mechanisms in the entire brain and
how these mechanisms are triggered needs to be determined.
Because most brain cells are dead in the ischemic region several
days after the stroke onset, inﬁltrating immune cells and reactive
glial cells could be major players in the tissue repair. In practice,
accelerating their effect is a potential next generation therapeutic
strategy, and direct in vivo reprogramming of reactive glial cells
into functional neurons after cerebral injury by retroviral trans-
duction of the NeuroD1 gene was recently reported (Guo et al.,
2014).
IL-10 and TGF-β are major anti-inﬂammatory molecules
in various organ injuries. Both are produced by inﬁltrating
immune cells and reactive glial cells after ischemic brain injury.
Viral overexpression of IL-10 in ischemic brain is neuroprotec-
tive (Ooboshi et al., 2006). One recent report demonstrated the
anti-inﬂammatory effect of TGF-β by inhibiting excessive neu-
roinﬂammation during the subacute phase of brain ischemia
(Cekanaviciute et al., 2014). Although the anti-inﬂammatory
effects of IL-10 and TGF-β have been pivotal, it remains to be
clariﬁed whether these effects last up to 1 week after the stroke
onset (Pál et al., 2012). If the mechanisms for stimulating TGF-β
and IL-10 expression can be controlled, this may become a strong
therapeutic method.
DEPLETION OF INFLAMMATORY MEDIATORS AND CELLS
Inﬁltrating immune cells and reactive glial cells produce various
inﬂammatory mediators. TNF-α and IL-1β directly induce neu-
ronal cell death. IL-23 and IL-1β activate T cell-mediated innate
immunity and promote secondary ischemic damage during the
subacute phase of ischemic brain injury (Shichita et al., 2009;
Konoeda et al., 2010). The existence of these inﬂammatory medi-
ators, including DAMPs, prolongs post-ischemic inﬂammation
and will be a threat to neuronal survival and repair. How-
ever, inﬂammatory mediator degradation mechanisms remain
mostly unknown. Inﬂammatory molecules may be degraded by
some enzymes or consumed by receptor-mediated endocytosis.
It is expected that nucleotides and lipids are rapidly metabo-
lized in the ischemic brain, and transfer by the blood stream
or cerebrospinal ﬂuid (CSF) will help to scavenge inﬂammatory
mediator. Further research should clarify the detailed mech-
anisms to scavenge inﬂammatory molecules produced in the
ischemic brain, and antibody therapy will be a pivotal thera-
peutic method targeting this potential mechanism. TNF-α and
IL-23 neutralizing antibody have been used clinically for rheuma-
toid arthritis and psoriasis patients, respectively. Natalizumab
is the neutralizing antibody for integrin-α4, which is neces-
sary for T cell inﬁltration into the inﬂammatory tissue, and has
already been used for multiple sclerosis (Yednock et al., 1992).
T cell depletion from ischemic brain has received attention as
a potential next generation therapy for ischemic stroke (Meisel
and Meisel, 2011; Wei et al., 2011). Thus, antibody therapies
may be used to help treat ischemic stroke patients in the near
future.
Activation of inﬂammasomes in immune cells induces the pro-
duction of IL-1β in its mature form, and ﬁnally results in the rapid
cell death of the same cells, which is called pyroptosis. Pyroptosis
may be a possible mechanism for the clearance of inﬂammatory
immune cells. This is supported by the fact that dying cells detected
using the TdT-mediated dUTP nick end labeling (TUNEL) stain-
ing method include macrophages and glial cells in the ischemic
brain (Mabuchi et al., 2000).
INDUCTION OF IMMUNE CELL REPAIR
The repair process for damaged brain tissues and regeneration
of neural cells takes place during resolution of inﬂammation. It
is difﬁcult to separate this process from the anti-inﬂammatory
mechanism, because they may overlap each other. We will fur-
ther discuss neuroprotective factors and repairing the damage to
immune cells.
NEUROPROTECTIVE FACTORS
Various growth factors are also produced by immune cells and
glial cells (Gudi et al., 2011). Among these, IGF-1 and FGF-2
are produced by inﬁltrating macrophages and microglia dur-
ing the recovery phase of ischemic brain injury (which occurs
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1 week after the stroke onset). IGF-1 and FGF-2 improve the
neurological outcome by saving neuron and glial cells from
cell death (Ness et al., 2004; Ikeda et al., 2005; Zhu et al., 2008;
Hill et al., 2012; Lalancette-Hébert et al., 2012). IGF-1 also
enhances repair after ischemic stroke by promoting neural regen-
eration, remyelination, and synaptogenesis (Lecker et al., 2007;
Zhu et al., 2008, 2009; Kooijman et al., 2009). Further inves-
tigation should clarify the mechanisms of IGF-1 and FGF-2
induction in the ischemic brain. Recently, transfer of mesenchy-
mal stem cells (MSCs) has been explored as a next generation
therapy for ischemic stroke (Kalladka and Muir, 2014). MSCs
produce various growth factors and promote neuronal survival
and neurogenesis (Calió et al., 2014). By improving the transfer
method, cell therapy may become a pivotal therapeutic strategy
(Guo et al., 2013).
The neuroprotective effect of prostaglandin E2 (PGE2) and
its receptor signaling pathway has received recent attention.
PGE2 has an effect via four distinct G protein-coupled EP
receptors (E-prostanoid: EP1, EP2, EP3, and EP4). The activa-
tion of EP2 signaling has a neuroprotective effect in ischemic
brain injury, which was shown in the signiﬁcant increase in
infarct volume in mice lacking the EP2 receptor (McCullough
et al., 2004). Similarly, signaling via the EP4 receptor, which is
expressed in both neurons and ischemic endothelial cells, has
neuroprotective effects against ischemic brain injury (Liang et al.,
2011). The administration of an EP4 agonist reduces infarct vol-
ume and neurological deﬁcits. In a neonatal hypoxic-ischemic
encephalopathy model, the inhibition of EP1 receptor signal-
ing or the activation of EP2, EP3, and EP4 receptor signaling
reveals attenuation of the ischemic injury (Taniguchi et al., 2011).
PGE2 and EP receptor signaling pathways have various func-
tions, which are dependent on distinct pathology of cerebral
diseases (Furuyashiki and Narumiya, 2011). Targeting speciﬁc
EP receptors in ischemic brain may become a novel therapeutic
method.
Similar to PGE2, some lipids have been reported to have anti-
inﬂammatory effects and promote neuroregeneration (Serhan,
2014). Cerebral ischemia increases PLA2 activity, which results in
the hydrolysis of phospholipids in the cellular membrane (Shanta
et al., 2012). Although the PLA2 effect itself is cytotoxic because
it disrupts the cellular membrane, PLA2 also generates docosa-
hexaenoic acid (DHA) derivatives and lysophospholipids through
phospholipid hydrolysis (Bonventre et al., 1997). Resolvin and
Neuroprotectin have been investigated for their anti-inﬂammatory
function in ischemic stroke (Marcheselli et al., 2003; Bazan, 2009).
Lysophospholipids also increase in ischemic brain and promote
neurite outgrowth (Ikeno et al., 2005; Spohr et al., 2011; Shanta
et al., 2012). Regulating the effect of these lipids is expected for the
resolution of post-ischemic inﬂammation.
NEUROPROTECTIVE CELLS
Inﬂammatory DAMPs activate glial cells and inﬁltrating immune
cells to promote post-ischemic inﬂammation. Paradoxically, this
mechanism results in the inﬁltrating macrophage cell death and
also induces anti-inﬂammatory and tissue-repairing immune cells.
Immune cell activation also induces anti-inﬂammatory cells.
These cells have been called M2 macrophages, in contrast to the
inﬂammatory M1 macrophages. Many researches have described
the M2 macrophage markers; these markers include: arginase-
1 (Arg1), chitinase3l3 (Ym), and Relmα (Fizz1). These markers
are intracellular enzymes that are implicated in collagen synthesis
and cell division; therefore, M2 enzymes are considered to pro-
mote tissue repair. Arg1 is the only marker that was reported
to function as a neuroprotective enzyme (Estévez et al., 2006).
However, these M2 markers may not be a good indicator for
recovery after ischemic stroke. M2 markers are rapidly expressed
in macrophages by TLR activation or other pattern recognition
receptors, which also induce inﬂammatory cytokine expression
(Hu et al., 2012). M2 markers appear in ischemic brain mostly
during the same phase as the inﬂammatory mediators, the M1
markers, are expressed. In addition, the transfer of M2 marker
positive-macrophages has not been reported to be sufﬁciently
neuroprotective (Desestret et al., 2013).
During post-ischemic inﬂammation, some populations of
macrophages and microglia become neuroprotective (Lalancette-
Hébert et al., 2007). Galectin-1 has been suggested to be
an inducer of anti-inﬂammatory macrophage/microglial cells
(Starossom et al., 2012; Quintá et al., 2014). Galectin-1 is pro-
duced by astrocytes and has a neuroprotective effect against
ischemic brain damage (Qu et al., 2011). Thus, the resolu-
tion of post-ischemic inﬂammation can be enhanced by the
induction of a speciﬁc macrophage/microglial cell population.
However, it is not clear whether the M2 markers truly reﬂect
the neuroprotective function of macrophages and microglial
cells. Suppressing inﬂammation alone is not enough to pro-
tect the brain from ischemic injury. IGF-1 and FGF-2 pro-
duction seems to be a good index of repairing function
(Lalancette-Hébert et al., 2012).
Further study is required to clarify whether sufﬁcient clear-
ance of inﬂammatory mediators (including DAMPs) begins
neuronal regeneration after ischemic stroke. A recent study
has suggested that there is a relationship between TLR activa-
tion and neuronal repair (Bohacek et al., 2012). It is possible
that DAMPs triggers the secondary signals, which lead to res-
olution of post-ischemic inﬂammation, even if the primary
signals via pattern recognition receptors promote ischemic dam-
age. What is this mechanism? The role of immune cells, other
than macrophages and microglia in part of the repair process,
is not fully understood. This understanding may be critical
for the establishment of next generation therapies for ischemic
stroke.
CONCLUSION
Immunity and various physiologicalmechanisms are implicated in
the triggering, persistence, and resolutionof post-ischemic inﬂam-
mation. Recent accumulating evidences clarify the complexity of
these mechanisms to understand the entire mechanisms. They will
show promising potential targets to develop therapies for ischemic
stroke.
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